《大行報告》瑞銀:港交所(00388.HK)第三季業績強勁 大致符預期
瑞銀發表研究報告指,港交所(00388.HK)第三季純利按年增長52%至33億元,大致符合該行預期。收入亦大致符合預期,其現金及衍生產品核心業務處於正軌。現金收入按年增長98%,增幅略高於市場成交,部分原因是受到互聯互通推動。北向及南向的日均成交額同樣創有紀錄以來新高,分別按年增長2.03倍及1.83倍。債券通交易量按年增長36%。
在強勁的牛熊證及衍生工具交易量推動下,衍生產品收入上升10%,但部分被期交所交易的期貨所抵銷。EBITDA利潤率則由第二季的78%輕微改善至78.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.